0001209191-18-022169.txt : 20180329
0001209191-18-022169.hdr.sgml : 20180329
20180329202326
ACCESSION NUMBER: 0001209191-18-022169
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180329
FILED AS OF DATE: 20180329
DATE AS OF CHANGE: 20180329
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: PRASAD SUYASH
CENTRAL INDEX KEY: 0001679129
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37833
FILM NUMBER: 18724562
MAIL ADDRESS:
STREET 1: C/O AUDENTES THERAPEUTICS, INC.
STREET 2: 101 MONTGOMERY ST., SUITE 2650
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94104
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Audentes Therapeutics, Inc.
CENTRAL INDEX KEY: 0001628738
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 461606174
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 600 CALIFORNIA ST., 17TH FLOOR
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94108
BUSINESS PHONE: 415-638-6556
MAIL ADDRESS:
STREET 1: 600 CALIFORNIA ST., 17TH FLOOR
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94108
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2018-03-29
0
0001628738
Audentes Therapeutics, Inc.
BOLD
0001679129
PRASAD SUYASH
C/O AUDENTES THERAPEUTICS, INC.
600 CALIFORNIA STREET, 17TH FLOOR
SAN FRANCISCO
CA
94108
0
1
0
0
Senior VP & Chief Med Officer
Common Stock
2018-03-29
4
M
0
7800
0.79
A
7800
D
Common Stock
2017-03-29
4
S
0
7800
30.025
D
0
D
Stock Option (right to buy)
0.79
2018-03-29
4
M
0
7800
0.00
D
2024-02-18
Common Stock
7800
70870
D
This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person.
Represents the weighted average sale price. The lowest price at which shares were sold was $30.00 and the highest price at which shares were sold was $30.16. The reporting person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.
The option vested as to 25% of the total shares on February 18, 2015, and then 6.25% of the total shares vest quarterly thereafter, with 100% of the total shares vested and exercisable on February 18, 2018, subject to the reporting person's provision of service to the issuer on each vesting date.
/s/ Thomas Soloway as attorney-in-fact for Suyash Prasad
2018-03-29